RGA has published new in-depth research quantifying the mortality and morbidity impacts of incretin-based therapies, including GLP-1s, that are approved as anti-obesity medications (AOMs) and diabetes treatments. The study examined data from four major markets to assess how widespread adoption of AOMs could affect population health outcomes over the next two decades.
RGA GLP-1 Study: Weighing the Evidence
by Richard Russell, Andrew Gaskell, Raman Lalia, Craig Armstrong, Chris Falkous, Dr. John J. Lefebre, Matt Battersby, Marilda Kotze
